¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"systemic inflammatory response syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® dumping syndrome ÇÑ±Û ´ýÇÎÁõÈıº
¼³¸í   
  ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº È¯ÀÚ¿¡°Ô¼­ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼­ ÀÛÀºÃ¢ÀڷΠÃß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒÈ­°üÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇϰԠ´Ã¾î³ªµç°¡, È­ÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒÈ­°üÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÁַΠ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù.
¿µ¹® Raynaud syndrome ÇÑ±Û ·¹À̳ëÁõÈıº
¼³¸í   
  »çÁöÀÇ ´ëĪÀû Ã»»öÁõÀ» Æ¯Â¡À¸·Î Çϴ Áõ»óÀ¸·Î¼­ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î Ã»»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù.
¿µ¹® battered child syndrome ÇÑ±Û ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº
¼³¸í   
  ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ­ ½ÅüÀûÀΠÇд븦 ¹Þ¾Æ ¹ß»ýÇϴ °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »ó󸦠¹ÞÀº ½Ã±â°¡ ¼­·Î Â÷À̰¡ Àִ ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼­ °üÂûµÇ´Â °ÍÀ̠Ư¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀΠ°æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼­´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³­, ¹ÝÇ×Àû Åµµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼­´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄڿàÁßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼­´Â ºó°ï, ºÎºÎ ºÒÈ­, ÇÙ°¡Á·À̸鼭 »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
¿µ¹® congenital rubella syndrome ÇÑ±Û ¼±ÃµÇ³ÁøÁõÈıº
¼³¸í   
  ÀӽűⰣ Áß¿¡ »ê¸ð°¡ Ç³Áø¿¡ °É¸®¸é À̠dzÁø ¹ÙÀÌ·¯½º´Â Å¹ÝÀ» ÅëÇØ¼­ Å¾ƿ¡°Ô Àü´ÞµÇ¾î¼­ Å¾ÆÀǠdzÁø°¨¿°À» ÀÏÀ¸Å²´Ù. ÀӽŠù 3°³¿ù µ¿¾È, Æ¯È÷ ÀӽŠù´Þ¿¡ Å¾ư¡ Ç³ÁøÀÇ °¨¿°À» ¹ÞÀ¸¸é, ½Å»ý¾Æ¿¡¼­ ¼±Ãµ±âÇü, Áï ´«¿¡¼­ ÃÐÁ¡À» Á¤È®È÷ ¸ÂÃß¾îÁִ ·»ÁîÀÇ ¿ªÇÒÀ» Çϴ ¼öÁ¤Ã¼ÀǠȥŹ(¹é³»Àå), ½ÉÀå±âÇü, ±Í¸Ó°Å¸® ¹× ½ÉÇÑ Áö´É¹Ú¾àÀ» µ¿¹ÝÇϴ ¼ÒµÎÁõ µîÀÌ ¹ß»ýÇϴ ¼ö°¡ ¸¹´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systemic scleroderma
    Àü½ÅÇǺΰæÈ­Áõ
  • systemic sclerosis
    Àü½Å°æÈ­Áõ
  • systemic therapy
    Àü½Å¿ä¹ý
  • systemic treatment
    Àü½ÅÄ¡·á
  • systemic vein
    Àü½ÅÁ¤¸Æ, üÁ¤¸Æ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • brain stem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • syndrome
    ÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å¼º±âÁõÈıº
  • afferent loop syndrome
    µéâÀÚÁõÈıº
  • Alport syndrome
    ¾ËÆ÷Æ®ÁõÈıº
  • Asherman's syndrome
    (¢¡ intrauterine synechia) ¾Æ¼Å¸¸ÁõÈıº
  • carpal tunnel syndrome
    ¼Õ¸ñ±¼ÁõÈıº, ¼ö±Ù°üÁõÈıº
  • cauda equina syndrome
    ¸»ÃÑÁõÈıº, ¸¶¹ÌÁõÈıº
  • compartment syndrome
    ±¸È¹ÁõÈıº
  • contact urticaria syndrome
    Á¢Ã˵ε巯±âÁõÈıº
  • cubital tunnel syndrome
    ÆÈ²ß±¼ÁõÈıº
  • Cushing's syndrome
    Äí½ÌÁõÈıº
  • dialysis disequilibrium syndrome
    Åõ¼®ºÒ±ÕÇüÁõÈıº
  • dry eye syndrome
    ´«¸¶¸§ÁõÈıº
  • dumping syndrome
    ºü¸¥ºñ¿òÁõÈıº, ´ýÇÎÁõÈıº
  • fetal alcohol syndrome
    žƾËÄÚ¿ÃÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
  • progressive systemic sclerosis
    (¢¡systemic scleroderma) Àü½ÅÇǺΰæÈ­Áõ
  • systemic nodular panniculitis
    Àü½Å°áÀýÁö¹æÃþ¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • systemic scleroderma
    Àü½ÅÇǺΰæÈ­Áõ
  • systemic sclerosis
    (¢¡systemic scleroderma) Àü½ÅÇǺΰæÈ­Áõ
  • systemic therapy
    Àü½Å¿ä¹ý
  • systemic treatment
    Àü½ÅÄ¡·á
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    (¢¡secondary immune response) ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • brainstem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • approximate response
    ±Ù»ç¹ÝÀÀ
  • arousal reaction=arousal response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • bullous systemic lupus erythematosus
    ¼öÆ÷¼º Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • cutaneous systemic vasculitis
    ÇǺΠÀü½Å¼º(ù«Ý± îïãóàõ) Ç÷°ü¿°(úìηæú)
  • diffuse systemic sclerosis
    ±¤¹üÀ§ Àü½Å °æÈ­Áõ
  • drug-induced systemic lupus erythematosus
    ¾à¹°À¯¹ß Àü½Å¼ºÈ«¹Ý¼º ·çǪ½º
  • embolism,systemic
    Àü½Å¼º(îïãóàõ)
  • encephalopathy,portal-systemic
    ¹®¸Æ-Àü½Å¼º
  • idiopathic systemic fibrosis
    Àü½Å¼º Ư¹ß¼º(îïãóàõ ÷åÛ¡àõ) ¼¶À¯Áõ
  • infantile systemic hyalinosis
    ¿µ¾Æ Àü½Å¼º À¯¸®ÁúÁõ
  • infection, systemic
    Àü½Å°¨¿°
  • liver,portal-systemic encephalopathy
    ¹®¸Æ-Àü½Å¼º ³úº´Áõ(ÙþØæ-îïãóàõ ¡­)
  • neonatal systemic lupus erythematosus
    ½Å»ý¾Æ Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • non-organ specific or systemic
    Àå±â ºñƯÀ̼ºÀÇ, Àü½ÅÀûÀÇ
  • passive systemic anaphylaxis
    ¼öµ¿Àü½Å¾Æ³ªÇʶô½Ã½º
  • portal-systemic encephlopathy
    ¹®¸Æ-Àü½Å¼øÈ¯¼º ³úº´Áõ(Ú¦Øæ-îïãóâàü»àõ ÒàÜ»ñø)
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pleiotypic response
    ´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
  • primary immune response
    ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéó­Øóæ¹Óßëë)
  • primary response
    ÀÏÂ÷ ´ëÀÀ(ìéó­Óßëë)
  • SOS response
    SOS ´ëÀÀ(Óßëë)
  • staircase response
    °è´Ü ´ëÀÀ(Í­Ó«Óßëë)
  • stringent response
    ¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
  • tertiary response
    »ïÂ÷´ëÀÀ (ß²ó­Óßëë)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • lateral recess syndrome
    ¿ÜÃøÇÔ¿äÁõÈıº
  • Loeffler's eosinophilic syndrome
    ·ÚÇ÷¯È£»ê±¸ÁõÈıº
  • malabsorption syndrome
    Èí¼öÀå¾ÖÁõÈıº
  • Marfan's syndrome
    ¸¶¸£ÆÎÁõÈıº
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MS Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome...
SID single intradermal [test]; Society for Investigative Dermatology; sucrase-isomaltase deficiency; sud...
SS disulfide; sacrosciatic; saline soak; saline solution; saliva sample; saliva substitute; Salmonella-...
SSS scalded skin syndrome; secondary Sjogren syndrome; sick sinus syndrome; specific soluble substance; ...
RS radioscaphoid; random sample; rating schedule; Raynaud syndrome; recipient's serum; rectal sinus; re...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IBDQ Inflammatory Bowel Disease Questionnaire
ILVEN Inflammatory Linear Verrucous Epidermal Nevus
IAAA Inflammatory abdominal aortic aneurysm
IBC Inflammatory breast cancer
IBC Inflammatory breast carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inflammatory change
    ¿°Áõ º¯È­, ¿°Áõ¼º º¯È­
  • inflammatory diarrhea
    ¿°Áõ¼º ¼³»ç
  • inflammatory disorder
    ¿°Áõ¼º Àå¾Ö
  • inflammatory erythema
    ¿°Áõ¼º È«¹Ý
  • inflammatory gingival hyperplasia
    ¿°Áõ¼º Ä¡Àº Áõ½Ä
  • inflammatory hyperplasia
    ¿°Áõ¼º °úÇü¼º, ¿°Áõ¼º Áõ½Ä
    ¿°Áõ¿¡ ÀÇÇÏ¿© »ý±â´Â °úÇü¼º.
  • inflammatory joint disorder
    ¿°Áõ¼º °üÀý Àå¾Ö
  • inflammatory of jaw
    ÅÎÀÇ ¿°Áõ¼º
  • inflammatory papillary hyperpalsia
    ¿°Áõ¼º À¯µÎÁõ½Ä
    ¹ÝÀÀ¼º º´¼Ò·Î¼­ °¡Ã¶¼º º¸Ã¶¹°ÀÇ Áö¼ÓÀû »ç¿ë°ú °ü·ÃÀÌ ÀÖ´Ù. ÀÇÄ¡ ÇϹæ Á¡¸·¿¡ »ý±ä Ä­µð´ÙÁõÀº °æ±¸°³°¡ ÀÌ·¯ÇÑ Áõ½Ä¼º Á¶Á÷ ¹ÝÀºÀ» ÀÏÀ¸Å°´Â ÀڱؿøÀÌ µÈ´Ù. °æ±¸°³¿¡ ¸¹Àº ¼ÒÀ¯µÎÀÇ ºñÈİ¡ ³ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÚ°¥ ¸ð¾ç¿¡¼­ °áÀýÇü ºñÈÄ´Â ±¸°³¸é¿¡¼­´Â ±ºÁýÈ­µÇ¾î ³ªÅ¸³ª³ª Ä¡Á¶ Á¡¸·¿¡¼­´Â ´ú ¸íÈ®Çϰųª ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • inflammatory reaction
    ¿°Áõ ¹ÝÀÀ
    ¿°Áõ ÀÎÀÚ°¡ »ýü¿¡ ÀÛ¿ëÇÏ¸é »ýÃ¼Ãø¿¡´Â ¹æ¾î±â´ÉÀÌ »ý±ä´Ù. ±× ¿°Áõ¼Ò¿¡¼­ÀÇ Ç×ü³ª È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ µîÀÇ È­Çй°ÁúÀ» ÇÔÀ¯ÇÑ Ç÷Àå ¼ººÐÀ̳ª Á¶Á÷¾×ÀÇ ±¹¼ÒÀû »ïÃâ, ¹éÇ÷±¸ÀÇ Ä§À±, ȸº¹À» À§ÇÑ ¼¶À¯ Áõ»ý µîÀÇ »ýÃ¼Ãø¿¡ »ý±â´Â ¹ÝÀÀ Çö»óÀ» ¸»ÇÑ´Ù. ¿°Áõ ÀÎÀÚÀÇ Á¾·ù, ¾çÀ̳ª »ýÃ¼ÃøÀÇ »óÅ¿¡ µû¶ó¼­ ¿°Áõ ¹ÝÀÀÀÌ »ý±â´Â ¾ç»óÀº ´Ù¸£´Ù.
  • inflammatory resorption
    ¿°Áõ¼º Èí¼ö
  • inflammatory tissue
    ¿°Áõ Á¶Á÷
  • non-inflammatory
    ºñ¿°Áõ¼º
  • pelvic inflammatory disease
    °ñ¹Ý¿° Áúȯ
  • primary non-inflammatory, myogenous pain disorder
    ¿ø¹ß¼ºÀÇ ºñ¿°Áõ¼º ±ÙÀ° µ¿Åë Àå¾Ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
macrophage inflammatory protein <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other.
They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells.
They most likely also play a significant role in respiratory tract defenses.
(20 Sep 2002)
pelvic inflammatory disease <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections.
(27 Sep 1997)
chronic inflammatory demyelinating polyneuropathy An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone.
(05 Mar 2000)
chronic inflammatory polyneuropathy <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response.
The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable.
Origin: Gr. Pathos = disease
(27 Sep 1997)
non-steroidal anti-inflammatory <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions.
Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate.
A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity.
Acronym: NSAID
(05 May 2002)
non-steroidal anti-inflammatory drug <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions.
Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate.
A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity.
Acronym: NSAID
(05 May 2002)
desquamative inflammatory vaginitis An acute inflammation of the vagina of unknown cause, characterised by grayish pseudomembrane, free discharge, and easy bleeding on trauma; the discharge contains pus and immature epithelial cells, although oestrogen levels are normal.
Vaginitis emphysematosa, vaginitis characterised by accumulation of gas in small connective tissue spaces lined by foreign-body giant cells.
Synonym: pachyvaginitis cystica, vaginitis cystica.
(05 Mar 2000)
disease, pelvic inflammatory Despite its seeming lack of gender, this term is applied to women only. PID refers exclusively to ascending infection of the female genital tract above the cervix.
(12 Dec 1998)
inflammatory <pathology> Inflammation is the reaction of living tissues to injury, infection or irritation. Inflamed tissues are characterised by pain, swelling, redness and heat. Anything that stimulates the inflammatory response is said to be inflammatory.
See: inflammation.
(11 Jun 1998)
inflammatory bowel disease <disease> A general term that encompasses several disease processes, most commonly, ulcerative colitis and Crohn's disease.
(27 Sep 1997)
inflammatory bowel diseases Chronic, non-specific disorders of unknown aetiology. Includes crohn disease and ulcerative colitis. Extracolonic manifestations are often associated with inflammatory bowel disease (ibd) and involve the liver, joints and skin.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á